IP Library Granted Patent US 7,939,095
Granted Patent B2
US 7,939,095 · App. 11/614,395 · Granted May 10, 2011

Crosslinked silane coating for medical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,939,095
App. No.
11/614,395
Granted
May 10, 2011
Kind
B2
Abstract

Coatings are provided in which surfaces may be activated by covalently bonding a combination ofsilane derivatives (A) to the metal surface, covalently bonding a lactone polymer (B) to the silane derivative by in situ ring opening polymerization, and depositing at least one layer of a polyester (C) on the bonded lactone polymer. Biologically active agents or therapeutic compounds may be deposited with any of the polyester layers. Such coated surfaces may be useful in medical devices, in particular stents.

Claims (4)

1. A composition comprising crosslinked silane derivatives linked to a surface having at least two functional terminals comprising an epoxide group and a sulfhydryl group, wherein the sulfhydryl group is oxidized to form sulfonic acid which serves as an in situ catalyst for ring opening polymerization, in suitable solvent or in bulk, to graft a first lactone polymer layer, and a second polymer layer is at least one of deposited, coated or sprayed on top of the first polymer layer, said second polymer layer having a therapeutic agent contained therein, the total thickness of the composition being in the range of about 0.01 to about 100 micrometers and wherein the weight of the therapeutic agent is in the range from about 0.1 to about 500 micrograms per square centimeter of surface area.

2. The composition of claim 1 wherein the therapeutic agent comprises an anti-proliferative agent.

3. The composition of claim 1 wherein the therapeutic agent comprises an anti-inflammatory agent.

4. The composition of claim 1 wherein the therapeutic agent comprises an anti-thrombotic drug.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →